CA2161011A1 - Xanthine derivatives - Google Patents

Xanthine derivatives

Info

Publication number
CA2161011A1
CA2161011A1 CA002161011A CA2161011A CA2161011A1 CA 2161011 A1 CA2161011 A1 CA 2161011A1 CA 002161011 A CA002161011 A CA 002161011A CA 2161011 A CA2161011 A CA 2161011A CA 2161011 A1 CA2161011 A1 CA 2161011A1
Authority
CA
Canada
Prior art keywords
compound
compounds
mmol
270mhz
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002161011A
Other languages
English (en)
French (fr)
Inventor
Fumio Suzuki
Nobuaki Koike
Junichi Shimada
Joji Nakamura
Shizuo Shiozaki
Shigeto Kitamura
Shunji Ichikawa
Hiroshi Kase
Hiromi Nonaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2161011A1 publication Critical patent/CA2161011A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002161011A 1994-02-23 1995-02-23 Xanthine derivatives Abandoned CA2161011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25736/94 1994-02-23
JP2573694 1994-02-23

Publications (1)

Publication Number Publication Date
CA2161011A1 true CA2161011A1 (en) 1995-08-31

Family

ID=12174110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002161011A Abandoned CA2161011A1 (en) 1994-02-23 1995-02-23 Xanthine derivatives

Country Status (7)

Country Link
US (1) US5703085A (https=)
EP (1) EP0698607B1 (https=)
AT (1) ATE218139T1 (https=)
AU (1) AU1823895A (https=)
CA (1) CA2161011A1 (https=)
DE (1) DE69526822T2 (https=)
WO (1) WO1995023148A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
KR101098209B1 (ko) 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
EP1709966A4 (en) * 2003-12-09 2009-04-29 PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION
US20070149555A1 (en) * 2004-03-30 2007-06-28 Kyowa Hakko Kogyo Co., Ltd Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
KR20070083714A (ko) 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
CA2724008A1 (en) * 2008-01-11 2009-09-11 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as trpv3 modulators
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
US10184028B2 (en) 2016-01-11 2019-01-22 Industrial Technology Research Institute Method for preparing a polymer
US9994679B2 (en) * 2016-01-11 2018-06-12 Industrial Technology Research Institute Polymerization process of polyarylene sulfide
US10377705B2 (en) 2016-01-11 2019-08-13 Industrial Technology Research Institute Method for preparing polyarylene sulfide (PAS) monomer
US10287396B2 (en) 2016-01-11 2019-05-14 Industrial Technology Research Institute Polymer
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2130138T3 (es) * 1990-10-18 1999-07-01 Kyowa Hakko Kogyo Kk Derivado de xantina.
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
ES2176204T3 (es) * 1992-07-08 2002-12-01 Kyowa Hakko Kogyo Kk Antidepresivos que contienen un derivado de xantina.
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists

Also Published As

Publication number Publication date
US5703085A (en) 1997-12-30
WO1995023148A1 (en) 1995-08-31
EP0698607A4 (https=) 1996-03-27
DE69526822D1 (en) 2002-07-04
AU1823895A (en) 1995-09-11
EP0698607B1 (en) 2002-05-29
EP0698607A1 (en) 1996-02-28
DE69526822T2 (de) 2003-01-23
ATE218139T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
EP0698607B1 (en) Xanthine derivative
US5587378A (en) Therapeutic agent for Parkinson's disease
EP0590919B1 (en) Therapeutic agents for parkinson's disease
US5543415A (en) Antidepressants
CA2024381C (en) Xanthine compounds
JPWO1995023148A1 (ja) キサンチン誘導体
US5670498A (en) 8-substituted styryl xanthine derivatives
US5525607A (en) Xanthine compounds
US6545000B1 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivatives
JP2613352B2 (ja) パーキンソン病治療剤
JP4769728B2 (ja) Ａ２ｂアデノシンレセプターアンタゴニスト
JPWO1994001114A1 (ja) うつ病治療剤
HK1000600B (en) Xanthine compounds
JP2980658B2 (ja) ｓ―トリアゾロ〔３，４―ｉ〕プリン誘導体
EP0449175B1 (en) Selective adenosine receptor agents
JP2988683B2 (ja) イミダゾキノロン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued